Who are Wellcovorin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trimethoprim, Gentamicin, Klaron, Methotrexate + Methylprednisolone, Systemic corticosteroids/methotrexate, Methotrexate + targeted therapy administration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/leucovorin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Wellcovorin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Wellcovorin (leucovorin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Folate Analog. Area: Oncology.

marketed Folate Analog Dihydrofolate reductase Oncology Live · refreshed every 30 min

Target snapshot

Wellcovorin (leucovorin) — Pfizer Japan Inc.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Wellcovorin TARGET	leucovorin	Pfizer Japan Inc	marketed	Folate Analog	Dihydrofolate reductase	1952-01-01
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	marketed	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	marketed	gentamicin	Dihydrofolate reductase	1970-01-01
Klaron	SULFACETAMIDE	Merck & Co.	marketed	Sulfonamide Antibacterial	Dihydrofolate reductase	1945-01-01
Methotrexate + Methylprednisolone	Methotrexate + Methylprednisolone	Université Catholique de Louvain	marketed	Antimetabolite + Corticosteroid combination	Dihydrofolate reductase (methotrexate); Glucocorticoid receptor (methylprednisolone)
Systemic corticosteroids/methotrexate	Systemic corticosteroids/methotrexate	Merck KGaA, Darmstadt, Germany	marketed	Immunosuppressant combination (corticosteroid + DMARD)	Glucocorticoid receptor (corticosteroids); dihydrofolate reductase (methotrexate)
Methotrexate + targeted therapy administration	Methotrexate + targeted therapy administration	University Hospital, Strasbourg, France	marketed	Combination chemotherapy with targeted agent	Dihydrofolate reductase (methotrexate component); targeted agent varies by protocol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Folate Analog class)

Acrotech Biopharma · 1 drug in this class
Pfizer Japan Inc · 1 drug in this class
Spectrum Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Wellcovorin — Competitive Intelligence Brief. https://druglandscape.com/ci/leucovorin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing